Published in Diabetes Week, April 17th, 2006
An agreement for a multinational phase 3 clinical trial of Spherix's Naturlose as a type 2 diabetes drug is being finalized. Preliminary work is underway and patient recruitment is expected to begin before year-end.
Last November, the U.S. Food and Drug Administration (FDA) approved the phase 1 and phase 2 clinical trial data submitted by Spherix, and authorized the Phase 3 clinical trial in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.